JP Morgan Chase’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $65.1M | Buy |
286,317
+21,967
| +8% | +$3.91M | ﹤0.01% | 1294 |
|
|
2026
Q1 | $42.2M | Buy |
264,350
+89,582
| +51% | +$16.6M | ﹤0.01% | 1498 |
|
|
2025
Q4 | $34.9M | Sell |
174,768
-142,411
| -45% | -$25.8M | ﹤0.01% | 1614 |
|
|
2025
Q3 | $49.6M | Buy |
317,179
+40,073
| +14% | +$6.36M | ﹤0.01% | 1421 |
|
|
2025
Q2 | $42M | Sell |
277,106
-481,286
| -63% | -$64.2M | ﹤0.01% | 1435 |
|
|
2025
Q1 | $114M | Buy |
758,392
+296,222
| +64% | +$49.7M | 0.01% | 878 |
|
|
2024
Q4 | $85.3M | Sell |
462,170
-20,575
| -4% | -$3.96M | 0.01% | 1015 |
|
|
2024
Q3 | $95.1M | Buy |
482,745
+85,759
| +22% | +$17.8M | 0.01% | 969 |
|
|
2024
Q2 | $82M | Buy |
396,986
+42,558
| +12% | +$9.64M | 0.01% | 1005 |
|
|
2024
Q1 | $96M | Buy |
354,428
+126,941
| +56% | +$30.3M | 0.01% | 957 |
|
|
2023
Q4 | $53.8M | Buy |
227,487
+26,146
| +13% | +$5.14M | 0.01% | 1182 |
|
|
2023
Q3 | $39.5M | Buy |
201,341
+27,983
| +16% | +$5.74M | ﹤0.01% | 1226 |
|
|
2023
Q2 | $36.4M | Sell |
173,358
-7,028
| -4% | -$1.4M | ﹤0.01% | 1273 |
|
|
2023
Q1 | $36.4M | Buy |
180,386
+43,786
| +32% | +$9.92M | ﹤0.01% | 1257 |
|
|
2022
Q4 | $29.8M | Sell |
136,600
-2,964
| -2% | -$647K | ﹤0.01% | 1388 |
|
|
2022
Q3 | $27.5M | Sell |
139,564
-18,407
| -12% | -$3.97M | ﹤0.01% | 1371 |
|
|
2022
Q2 | $33.8M | Sell |
157,971
-97,487
| -38% | -$23.8M | ﹤0.01% | 1261 |
|
|
2022
Q1 | $72.5M | Buy |
255,458
+99,525
| +64% | +$30.7M | 0.01% | 986 |
|
|
2021
Q4 | $58.8M | Sell |
155,933
-75,036
| -32% | -$29.2M | 0.01% | 1130 |
|
|
2021
Q3 | $95.3M | Buy |
230,969
+31,192
| +16% | +$13M | 0.01% | 889 |
|
|
2021
Q2 | $73.9M | Sell |
199,777
-48,381
| -19% | -$16.2M | 0.01% | 1032 |
|
|
2021
Q1 | $71.9M | Buy |
248,158
+57,446
| +30% | +$16M | 0.01% | 1005 |
|
|
2020
Q4 | $47.7M | Buy |
190,712
+45,231
| +31% | +$10.8M | 0.01% | 1096 |
|
|
2020
Q3 | $32.4M | Buy |
145,481
+29,497
| +25% | +$6.12M | 0.01% | 1201 |
|
|
2020
Q2 | $20.2M | Buy |
115,984
+18,436
| +19% | +$2.94M | ﹤0.01% | 1370 |
|
|
2020
Q1 | $12.3M | Buy |
97,548
+12,607
| +15% | +$1.89M | ﹤0.01% | 1585 |
|
|
2019
Q4 | $13M | Sell |
84,941
-48,181
| -36% | -$6.67M | ﹤0.01% | 1907 |
|
|
2019
Q3 | $17.6M | Buy |
133,122
+47,127
| +55% | +$6.32M | ﹤0.01% | 1687 |
|
|
2019
Q2 | $12M | Buy |
85,995
+145
| +0.2% | +$19.7K | ﹤0.01% | 1950 |
|
|
2019
Q1 | $12.5M | Buy |
85,850
+3,471
| +4% | +$456K | ﹤0.01% | 1862 |
|
|
2018
Q4 | $9.32M | Sell |
82,379
-44,517
| -35% | -$5.57M | ﹤0.01% | 2074 |
|
|
2018
Q3 | $17.1M | Buy |
126,896
+39,685
| +46% | +$4.9M | ﹤0.01% | 1789 |
|
|
2018
Q2 | $9.79M | Sell |
87,211
-24,727
| -22% | -$2.67M | ﹤0.01% | 2161 |
|
|
2018
Q1 | $11.9M | Sell |
111,938
-59,745
| -35% | -$6.44M | ﹤0.01% | 1898 |
|
|
2017
Q4 | $18.8M | Buy |
171,683
+2,291
| +1% | +$249K | ﹤0.01% | 1614 |
|
|
2017
Q3 | $18.1M | Sell |
169,392
-9,237
| -5% | -$949K | ﹤0.01% | 1571 |
|
|
2017
Q2 | $18.1M | Sell |
178,629
-87,878
| -33% | -$8.09M | ﹤0.01% | 1529 |
|
|
2017
Q1 | $24M | Sell |
266,507
-9,860
| -4% | -$837K | 0.01% | 1357 |
|
|
2016
Q4 | $21.1M | Buy |
276,367
+4,213
| +2% | +$320K | 0.01% | 1433 |
|
|
2016
Q3 | $22.7M | Buy |
272,154
+90,968
| +50% | +$7.63M | 0.01% | 1290 |
|
|
2016
Q2 | $14.9M | Buy |
181,186
+24,743
| +16% | +$2.04M | ﹤0.01% | 1594 |
|
|
2016
Q1 | $11.9M | Buy |
156,443
+105,399
| +206% | +$7.8M | ﹤0.01% | 1674 |
|
|
2015
Q4 | $4.1M | Sell |
51,044
-2,382
| -4% | -$172K | ﹤0.01% | 2344 |
|
|
2015
Q3 | $3.39M | Sell |
53,426
-118,371
| -69% | -$8.5M | ﹤0.01% | 2477 |
|
|
2015
Q2 | $12.1M | Buy |
171,797
+49,275
| +40% | +$3.65M | ﹤0.01% | 1787 |
|
|
2015
Q1 | $9.71M | Buy |
122,522
+17,841
| +17% | +$1.32M | ﹤0.01% | 1920 |
|
|
2014
Q4 | $6.66M | Buy |
104,681
+7,245
| +7% | +$454K | ﹤0.01% | 2218 |
|
|
2014
Q3 | $5.82M | Sell |
97,436
-40,757
| -29% | -$2.33M | ﹤0.01% | 2264 |
|
|
2014
Q2 | $7.39M | Buy |
138,193
+15,259
| +12% | +$837K | ﹤0.01% | 1890 |
|
|
2014
Q1 | $7.42M | Sell |
122,934
-230,983
| -65% | -$13.5M | ﹤0.01% | 1879 |
|
|
2013
Q4 | $18.8M | Buy |
353,917
+248,680
| +236% | +$12.5M | 0.01% | 1363 |
|
|
2013
Q3 | $4.87M | Buy |
105,237
+6,778
| +7% | +$311K | ﹤0.01% | 2199 |
|
|
2013
Q2 | $4.04M | Buy |
+98,459
| New | +$4.22M | ﹤0.01% | 2275 |
|
Other funds holding CRL
AI
JP Morgan Chase's CRL Position: Q2 2026 in Review
JP Morgan Chase increased its Charles River Laboratories (CRL) stake by 8.3% in Q2 2026, buying an estimated $3.91M and bringing the position to 286,317 shares worth $65.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1294.
JP Morgan Chase first reported a position in CRL in Q2 2013 and has held it in 53 quarters since. The position peaked at $114M in Q1 2025. 565 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- JP Morgan Chase held 286,317 shares of Charles River Laboratories worth $65.1M as of Q2 2026.
- JP Morgan Chase bought 21,967 Charles River Laboratories shares in Q2 2026, an estimated $3.91M.
- Charles River Laboratories made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1294 holding.
- JP Morgan Chase first reported a position in Charles River Laboratories in Q2 2013 and has held it in 53 quarters since.
- JP Morgan Chase's Charles River Laboratories position peaked at $114M in Q1 2025.
- 565 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.